Contrasting PAVmed (NASDAQ:PAVM) & Inogen (NASDAQ:INGN)

PAVmed (NASDAQ:PAVM) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for PAVmed and Inogen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1	1	1	0	2.00
Inogen	1	0	0	1	2.50

PAVmed currently has a consensus price target of $56.00, suggesting a potential upside of 1,008.91%. Given PAVmed’s higher probable upside, equities research analysts plainly believe PAVmed is more favorable than Inogen.

Risk & Volatility

PAVmed has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Inogen has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Earnings and Valuation

This table compares PAVmed and Inogen”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70,000.00	72.14	$400,000.00	($37.40)	-0.14
Inogen	$348.67 million	0.54	-$22.75 million	($0.91)	-7.63

PAVmed has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 13.4% of PAVmed shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares PAVmed and Inogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PAVmed	-21,914.12%	-146.19%	-18.39%
Inogen	-7.08%	-12.90%	-8.27%

Summary

Inogen beats PAVmed on 9 of the 15 factors compared between the two stocks.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.